DeepMed Research

Civitas Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Phase 1

Completed

Conditions: Multiple Sclerosis, Acute Relapsing

Interventions: Drug: rHIgM22
Drug: Placebo

First Posted Date: 2015-03-25

Last Posted Date: 2018-08-22

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 27

Registration Number: NCT02398461

Locations: 🇺🇸
Acorda Site #16, Centennial, Colorado, United States
🇺🇸
Acorda Site #22, Chicago, Illinois, United States
🇺🇸
Acorda Site #19, Teaneck, New Jersey, United States

and more 9 locations

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Phase 3

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: CVT-301
Other: Observational cohort

First Posted Date: 2015-02-02

Last Posted Date: 2019-05-28

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 408

Registration Number: NCT02352363

Locations: 🇺🇸
Acorda Site #7150, Baton Rouge, Louisiana, United States
🇺🇸
Acorda Site # 7142, Fountain Valley, California, United States
🇺🇸
Acorda Site #7131, Decatur, Georgia, United States

and more 73 locations

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Phase 2

Terminated

Conditions: Epilepsy

Interventions: Drug: diazepam nasal spray

First Posted Date: 2014-12-15

Last Posted Date: 2018-07-30

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 126

Registration Number: NCT02316847

Locations: 🇺🇸
Acorda Site #237, Philadelphia, Pennsylvania, United States
🇺🇸
Acorda Site #231, Tallahassee, Florida, United States
🇺🇸
Acorda Site #202, Bethesda, Maryland, United States

and more 30 locations

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

Phase 3

Completed

Conditions: Post-Ischemic Stroke

Interventions: Drug: Placebo
Drug: dalfampridine-ER 7.5mg
Drug: dalfampridine-ER 10mg

First Posted Date: 2014-10-22

Last Posted Date: 2018-06-07

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 377

Registration Number: NCT02271217

Locations: 🇺🇸
Acorda Site #109, Berkeley, California, United States
🇺🇸
Acorda Site #186, Atlanta, Georgia, United States
🇺🇸
Acorda Site #103, Miami, Florida, United States

and more 71 locations

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Phase 3

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: CVT-301

First Posted Date: 2014-09-17

Last Posted Date: 2019-08-14

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 325

Registration Number: NCT02242487

Locations: 🇺🇸
Acorda Site #5013, Boca Raton, Florida, United States
🇺🇸
Acorda Site #5040, Atlanta, Georgia, United States
🇺🇸
Acorda Site #5025, Chicago, Illinois, United States

and more 71 locations

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Phase 3

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: CVT-301 Low Dose
Other: Placebo
Drug: CVT-301 High Dose

First Posted Date: 2014-09-15

Last Posted Date: 2019-05-28

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 351

Registration Number: NCT02240030

Locations: 🇵🇱
Acorda Site #5301, Warsaw, Poland
🇺🇸
Acorda Site #5053, Aventura, Florida, United States
🇺🇸
Acorda Site #5044, Orlando, Florida, United States

and more 71 locations

A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure

Phase 1

Completed

Conditions: Heart Failure

Interventions: Other: Placebo
Drug: GGF2
Drug: Midazolam

First Posted Date: 2013-09-18

Last Posted Date: 2016-07-13

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 22

Registration Number: NCT01944683

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
🇺🇸
Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States

and more 5 locations

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

Phase 2

Completed

Conditions: Spasticity

Interventions: Drug: Placebo
Drug: Tizanidine
Drug: Moxifloxacin

First Posted Date: 2013-04-24

Last Posted Date: 2021-03-23

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 136

Registration Number: NCT01839279

Locations: 🇺🇸
Covance- Dallas, Dallas, Texas, United States

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: rHIgM22

First Posted Date: 2013-03-04

Last Posted Date: 2015-02-27

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 72

Registration Number: NCT01803867

Locations: 🇺🇸
Acorda Investigational Site, Seattle, Washington, United States

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

Phase 2

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: Placebo
Drug: CVT-301

First Posted Date: 2013-01-29

Last Posted Date: 2018-08-08

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 89

Registration Number: NCT01777555

Locations: 🇺🇸
Civitas Investigational Site 1014, Cleveland, Ohio, United States
🇺🇸
Civitas Investigational Site 1004, Boca Raton, Florida, United States
🇺🇸
Civitas Investigational Site 1002, Port Charlotte, Florida, United States

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy